The Migraine 360 Primary Care Training Course will explore best practices for diagnosis, options for acute and preventive management, and novel therapeutic options that are changing the current landscape for migraine treatment.
The Migraine 360 Primary Care Training Course will explore best practices for diagnosis, options for acute and preventive management, and novel therapeutic options that are changing the current landscape for migraine treatment.
Merle Diamond, MD, shares "what to expect" at the Migraine 360 Primary Care Training Course that will explore best practices for diagnosis, options for acute and preventive management, and more.
Merle Diamond, MD, shares "what to expect" at the Migraine 360 Primary Care Training Course that will explore best practices for diagnosis, options for acute and preventive management, and more.
David Weill, MD, discusses physician burnout, the effects of isolation, finding solace in faith, and the importance of connectedness with other physicians as well as personal family and friends.
David Weill, MD, discusses physician burnout, the effects of isolation, finding solace in faith, and the importance of connectedness with other physicians as well as personal family and friends.
In this 2-part series, Michael F Myers, MD, DLFAPA, interviews novelist and transplant surgery specialist, David Weill, MD, about his book Exhale that focuses on physician burnout and how it impacts mental health.
In this 2-part series, Michael F Myers, MD, DLFAPA, interviews novelist and transplant surgery specialist, David Weill, MD, about his book Exhale that focuses on physician burnout and how it impacts mental health.
In this video, Rajiv Ratan, MD, PhD, discusses his presentation given at the 146th Annual Meeting of the American Neurological Association titled “Harnessing Hypoxic Adaptation to Interdict Ferroptosis and Treat Neurological Diseases.”
In this video, Rajiv Ratan, MD, PhD, discusses his presentation given at the 146th Annual Meeting of the American Neurological Association titled “Harnessing Hypoxic Adaptation to Interdict Ferroptosis and Treat Neurological Diseases.”
In this video, S. Claiborne “Clay” Johnston, M.D, Ph.D, discusses his presentation at the 146th Annual Meeting of the American Neurological Association titled “Insights into Using Dual Antiplatelet Therapy in Patients with Acute Ischemic...
In this video, S. Claiborne “Clay” Johnston, M.D, Ph.D, discusses his presentation at the 146th Annual Meeting of the American Neurological Association titled “Insights into Using Dual Antiplatelet Therapy in Patients with Acute Ischemic...
In this video, Eva Feldman, MD, PhD, discusses her presentation at the 146th Annual Meeting of the American Neurological Association titled “Recent Advances in ALS.”
In this video, Eva Feldman, MD, PhD, discusses her presentation at the 146th Annual Meeting of the American Neurological Association titled “Recent Advances in ALS.”
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click